Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868295 | 0.94 | ADRA1D (0.57) | ADRA1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7259157 | 0.82 | ADRA1D (0.90) | ADRA1DSLC6A4 | |
| SCHEMBL4874301 | 0.80 | KDM4E (0.47) | ADRA1D | |
| SCHEMBL4872035 | 0.78 | ADRA1D (0.56) | ADRA1DSLC6A4 | |
| SCHEMBL14306777 | 0.78 | ADRA1D (0.80) | ADRA1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7255562 | 0.78 | ADRA1D (1.00) | ADRA1DSLC6A4 | |
| SCHEMBL6133590 | 0.78 | ADRA1D (0.71) | ADRA1DSLC6A4 | |
| SCHEMBL4873246 | 0.77 | ADRA1D (0.61) | ADRA1DSLC6A4 | |
| Hydrochloric Acid SCHEMBL7255365 | 0.77 | ADRA1D (0.80) | ADRA1DSLC6A4 | |
| SCHEMBL11007679 | 0.77 | ALDH1A1 (0.62) | ADRA1DSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-7148235-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-6939870-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | ADRA1D 106/4885SLC6A4 21/4885 |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | ADRA1D 119/4885SLC6A4 20/4885 |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | ADRA1D 119/4885SLC6A4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.